To confirm the findings described above in vivo, we employed an OVA mouse model of allergenic asthma, which represents a Th2 immune cell-driven inflammatory airway allergic response27, and compared the therapeutic potencies of a single intravenous injection of 3 × 105 hUC-MSCs expressing a control (shCTR) or ATF2-specific (shATF2) shRNA (Fig. 6a). This evidence concerns the gene ATF2 and asthma.